A matched-pair analysis reveals marginally reduced CD34+ cell mobilization on second occasion in 27 related donors who underwent peripheral blood stem cell collection twice at the same institution.
Adolescent
Adult
Aged
Antigens, CD34
/ analysis
Blood Transfusion
Cell Separation
Female
Hematopoietic Stem Cell Mobilization
/ methods
Hematopoietic Stem Cell Transplantation
Humans
Immunomagnetic Separation
Male
Matched-Pair Analysis
Middle Aged
Peripheral Blood Stem Cells
/ cytology
Retrospective Studies
Tissue Donors
Young Adult
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
04
05
2019
revised:
01
07
2019
accepted:
08
07
2019
pubmed:
19
10
2019
medline:
9
6
2020
entrez:
19
10
2019
Statut:
ppublish
Résumé
In a small proportion of cases, hematopoietic function is insufficient after allogeneic hematopoietic stem cell transplantation, as a result of poor graft function or graft failure. These complications are common indications of re-mobilization of the initial donor, either for a second allograft or for an infusion of CD34+ Selected stem Cell Boost (SCB). We retrospectively reviewed the results of two cycles of CD34+ cell mobilization and collection. CD34+ cells mobilized and collected at each cycle were compared. When CD34+ cell selection from the collected allogeneic mononuclear cells was indicated, it was performed with the Clinimacs Plus® medical device, and results from in-process and final quality checks were analyzed. To assess the efficacy of CD34+ SCB, transfusion needs before and after the infusion of selected CD34+ cells were calculated. The median peripheral blood concentration of CD34+ cells/μL was marginally reduced during the second cycle (35.6 vs 33.8, p < 0.05); results revealed a strong correlation between paired values (r = 0.85). The cumulative number of collected CD34+ cells were similar for both cycles; the total processed blood volume was higher during the second cycle (p = 0.023). For CD34+ immune-selection procedures, CD34+ cell recovery and purity were respectively 57% and 95%, with a median T-cell depletion of 6.7 log. Recipients' needs for platelet and red blood cell transfusions were significantly reduced after CD34+ SCB. This study confirms the feasibility of a second cycle of mobilization in healthy related donors and the benefits of CD34+ SCB on hematopoietic reconstitution.
Sections du résumé
BACKGROUND
In a small proportion of cases, hematopoietic function is insufficient after allogeneic hematopoietic stem cell transplantation, as a result of poor graft function or graft failure. These complications are common indications of re-mobilization of the initial donor, either for a second allograft or for an infusion of CD34+ Selected stem Cell Boost (SCB).
METHODS AND MATERIALS
We retrospectively reviewed the results of two cycles of CD34+ cell mobilization and collection. CD34+ cells mobilized and collected at each cycle were compared. When CD34+ cell selection from the collected allogeneic mononuclear cells was indicated, it was performed with the Clinimacs Plus® medical device, and results from in-process and final quality checks were analyzed. To assess the efficacy of CD34+ SCB, transfusion needs before and after the infusion of selected CD34+ cells were calculated.
RESULTS
The median peripheral blood concentration of CD34+ cells/μL was marginally reduced during the second cycle (35.6 vs 33.8, p < 0.05); results revealed a strong correlation between paired values (r = 0.85). The cumulative number of collected CD34+ cells were similar for both cycles; the total processed blood volume was higher during the second cycle (p = 0.023). For CD34+ immune-selection procedures, CD34+ cell recovery and purity were respectively 57% and 95%, with a median T-cell depletion of 6.7 log. Recipients' needs for platelet and red blood cell transfusions were significantly reduced after CD34+ SCB.
CONCLUSION
This study confirms the feasibility of a second cycle of mobilization in healthy related donors and the benefits of CD34+ SCB on hematopoietic reconstitution.
Substances chimiques
Antigens, CD34
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3442-3447Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2019 AABB.
Références
Larocca A, Piaggio G, Podestà M, et al. Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation. Haematologica 2006;91:935-40.
Sun YQ, He GL, Chang YJ, et al. The incidence, risk factors, and outcomes of primary poor graft function after unmanipulated haploidentical stem cell transplantation. Ann Hematol 2015;94:1699-705.
Ghobadi A, Fiala MA, Ramsingh G, et al. Fresh or cryopreserved CD34+-selected mobilized peripheral blood stem and progenitor cells for the treatment of poor graft function after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2017;23:1072-7.
Gaya A, Urbano-Ispizua A, Fernandez-Aviles F, et al. Anemia associated with impaired erythropoietin secretion after allogeneic stem cell transplantation: incidence, risk factors, and response to treatment. Biol Blood Marrow Transplant 2008;14:880-7.
Remberger M, Ringden O, Ljungman P, et al. Booster marrow or blood cells for graft failure after allogeneic bone marrow transplantation. Bone Marrow Transplant 1998;22:73.
Arseniev L, Tischler HJ, Battmer K, et al. Treatment of poor marrow graft function with allogeneic CD34+ cells immunoselected from G-CSF-mobilized peripheral blood progenitor cells of the marrow donor. Bone Marrow Transplant 1994;14:791-7.
Mohty M, Faucher C, Chabannon C, et al. CD34+ immunoselected cells for poor graft function following allogeneic BMT. Cytotherapy 2000;2:367-70.
Milone G, Tornello A, Leotta S, et al. CD34+ selected haematopoietic stem cell (HSC) not preceded by any immunosuppressive therapy as effective treatment for graft failure. Bone Marrow Transplant 2005;35:521.
Bailén R, Pérez-Corral AM, Pascual C, et al. Factors predicting peripheral blood progenitor cell mobilization in healthy donors in the era of related alternative donors: experience from a single center. J Clin Apher 2019;34:373-80.
De la Rubia J, Arbona C, Del Cañizo C, et al. Second mobilization and collection of peripheral blood progenitor cells in healthy donors is associated with lower CD34+ cell yields. J Hematotherapy Stem Cell Res 2002;11:705-9.
Anderlini P, Lauppe J, Przepiorka D, et al. Peripheral blood stem cell apheresis in normal donors: feasibility and yield of second collections. British J Haematol 1997;96:415-7.
Tichelli A, Passweg J, Hoffmann T, et al. Repeated peripheral stem cell mobilization in healthy donors: time-dependent changes in mobilization efficiency. British J Haematol 1999;106:152-8.
Stroncek DF, Clay ME, Herr G, et al. Blood counts in healthy donors 1 year after the collection of granulocyte-colony-stimulating factor-mobilized progenitor cells and the results of a second mobilization and collection. Transfusion 1997;37:304-8.
Sutherland DR, Anderson L, Keeney M, et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematotherapy 1996;5:213-26.
Haen SP, Schumm M, Faul C, et al. Poor graft function can be durably and safely improved by CD34+-selected stem cell boosts after allogeneic unrelated matched or mismatched hematopoietic cell transplantation. J Cancer Res Clin Oncol 2015;141:2241-51.
Guardiola P, Kuentz M, Garban F, Blaise D, Reiffers J, Attal M, et al. Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia. Br J Haematol 2000;111:292-302.
Wolff SN. Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation. Bone Marrow Transplant 2002;29:545-52.
Schriber J, Agovi MA, Ho V, et al. Second unrelated donor hematopoietic cell transplantation for primary graft failure. Biol Blood Marrow Transplant 2010;16:1099-106.
Stroncek DF, Tran M, Frodigh SE, et al. Preliminary evaluation of a highly automated instrument for the selection of CD34+ cells from mobilized peripheral blood stem cell concentrates. Transfusion 2016;56:511-7.
Klyuchnikov E, El-Cheikh J, Sputtek A, et al. CD34+-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies. Biol Blood Marrow Transplant 2014;20:382-6.
Stasia A, Ghiso A, Galaverna F, et al. CD34 selected cells for the treatment of poor graft function after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2014;20:1440-3.
Liu X, Wu M, Peng Y, et al. Improvement in poor graft function after allogeneic hematopoietic stem cell transplantation upon administration of mesenchymal stem cells from third-party donors: a pilot prospective study. Cell Transplant 2014;23:1087-98.